Abstract
Recent reports to the Therapeutic Goods Administration (TGA) and state and territory safety surveillance systems, along with data from the Australian Immunisation Register (AIR), indicate that some respiratory syncytial virus (RSV) immunisation products have been used incorrectly. This statement provides guidance on actions following inadvertent administration of the incorrect product, as well as clinical guidance in Appendix 1.
Recommendation
Western Pacific
Australia
RSV (Respiratory syncytial virus)
